The funds will be used for the preclinical development of m102.4, an antibody indicated as a post-exposure prophylactic against Nipah or Hendra virus infection, that can lead to respiratory and encephalitis disease.
M102.4 is a fully human antibody that potently neutralizes all available NiV and HeV isolates in vitro and provides post-exposure protection in several animal models for NiV and HeV infection.
M102.4 was first identified at the Uniformed Services University and the National Cancer Institute.